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Objective: We evaluated the safety and efficacy of the fibrin sealant Beriplast P (FSBP; Aventis-Behring) for hemostasis in
anastomosis of polytetrafluoroethylene (PTFE) grafts to the femoral artery.
Methods: In a single-blinded randomized prospective multicenter clinical trial, FSBP was compared with thrombin-soaked
gelatin sponge (TSG) for efficacy in stopping bleeding from needle or suture holes in PTFE grafts after anastomosis to
the femoral artery. Patients were randomized to FSBP application, which requires a 3-minute period of arterial clamping
to enable the fibrin clot to adhere, or to TSG application, which requires pressure from gauze sponges, after completion
of the femoral artery anastomosis. The primary end point was hemostasis, defined as absence of any detectable bleeding
as judged by the operating surgeon, by 4 minutes after randomization. Secondary end points included actual time from
randomization to hemostasis, time to beginning of wound closure, measured blood loss (weighed sponges), incidence of
recurrent bleeding, stay in the intensive care unit, and hospital length of stay. Data were analyzed with the intention-to-
treat method.
Results: Two hundred thirty-five subjects were enrolled at 26 medical centers; 34 were subsequently excluded from the
study. Of the 201 randomized subjects, 100 received FSBP and 99 received TSG. Hemostasis was achieved by 4 minutes
in 64 subjects (63%) in the FSBP group and 40 subjects (40%) in the TSG group (P  .0018). In the FSBP group,
compared with the TSG group, time to hemostasis was shorter (median, 4.0 minutes; 95% confidence interval [CI],
3.8-4.18 minutes vs median, 5.6 minutes, 95% CI, 4.5-7.0; P  .008), blood loss was less (mean, 4.0  29.7 g vs mean,
15.6  28.4 g; P < .0001), and time to wound closure was shorter (median, 15 minutes; 95% CI, 10.47-18.67 minutes
vs median, 22.8 minutes; 95% CI, 18.67-30.67; P  .005). There were no differences in recurrent bleeding or any other
adverse events. There was no significant difference in ICU stay, but hospital length of stay was shorter in the FSBP group
compared with the TSG group, and the difference approached significance (median, 6.5 days; 95% CI, 5.00-7.00 days vs
median, 7.0 days; 95% CI,. 6.00-8.00 days; P  .0565).
Conclusion: FSBP is more effective than TSG for achieving hemostasis of needle or suture hole bleeding from PTFE
femoral artery grafts. (J Vasc Surg 2003;38:766-71.)
Hemostasis in peripheral vascular surgery is made more
difficult by the need for direct arterial and arterial graft
suturing as well as by systemic anticoagulation to prevent
thrombosis during periods of vascular occlusion. Suture
line bleeding in arterial surgery is primarily controlled with
precise suture technique, including use of fine suture ma-
terial and needles. To assist with control of residual bleed-
ing after suturing of arterial operative sites, various topical
hemostatic aids are in use.
One approach to topical hemostasis is use of agents that
provide a mechanical scaffold on which autogenous throm-
bus can form; examples include oxidized cellulose, gelatin,
and bovine collagen. Another approach to topical hemo-
stasis is use of an agent that enhances or accelerates forma-
tion of autogenous thrombus, such as topical thrombin,
which can be used in conjunction with scaffolding-type
agents. An alternative approach to topical hemostasis is use
of an agent that actively forms thrombus, without need for
any autogenous component or activation. Fibrin sealant,
available in a variety of forms, is such an agent. Fibrin
sealant includes separate solutions of fibrinogen and throm-
bin, which when mixed and applied to operative sites results
in formation of fibrin clot.
Originally made by mixing pooled cryoprecipitate and
bovine thrombin, a number of fibrin sealants are now
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commercially available. These agents have improved viral
safety and increased fibrinogen concentration, compared
with cryoprecipitate, and most contain human thrombin,
which eliminates concerns about sensitivity to bovine prod-
ucts. These agents have been used in a variety of surgical
settings.1-4 The fibrin sealant Beriplast P (FSBP; Aventis
Behring, Strasbourg, France) includes fibrinogen, throm-
bin, fibrin stabilizing factor XIII, aprotinin, and calcium
chloride, and is available for clinical use in many countries.
Despite the availability of these agents, demonstration
of their efficacy in arterial vascular surgery has been prob-
lematic. Patient safety and surgical ethics prevent applica-
tion of topical agents to actively bleeding arterial sites, with
untreated control sites. A clinically relevant model is
needed in which topical hemostatic agents can be com-
pared without compromising patient safety.
Extruded polytetrafluoroethylene (PTFE) grafts have
been available since the early 1970s and are widely used.
Despite their popularity, the structure of PTFE is such that
sealing of the graft around needle and suture holes is
imperfect, and bleeding from these holes around the su-
tures is predictable, and requires time to control and in-
creased operative blood loss.5,6 The actual volume of
bleeding varies, but usually is small and can be quantified,
and an alternate method of hemostasis can be applied
(direct pressure). Because of these features, suture- and
needle-hole bleeding from PTFE grafts provides a clinically
relevant but safe setting in which to test the efficacy of
topical hemostatic agents. A human clinical research evalu-
ation of the safety and efficacy of FSBP compared with
thrombin-soaked gelatin sponge (TSG; Gelfoam; Pharma-
cia and Upjohn, Kalamazoo, Mich) for control of needle-
and suture-hole bleeding from PTFE grafts to the femoral
artery forms the basis for this report.
METHODS
Origins/control of study/data
The present study was intended to test the safety and
efficacy of FSBP and to provide data to possibly support
application to the US Food and Drug Administration for
approval for use of FSBP in hemostasis in vascular surgery.
The protocol was designed by the investigators at a meeting
convened by the manufacturer-sponsor for that purpose.
Use of TSG as the control treatment was chosen by con-
sensus of the investigators as the most effective currently
approved active topical hemostatic aid. The data were col-
lected by the investigators. Data analysis was performed by
one of the authors (G.M.-V.), an employee of the manu-
facturer-sponsor. The principal investigator (L.M.T.) par-
ticipated in all phases of the data analysis and had access to
all study data, as did all of the coinvestigators. This report
was written by the principal investigator, with approval and
suggestions from the coauthors and coinvestigators. The
decision to publish the results and the choice of the journal
to which this report was submitted was made by the prin-
cipal investigator, with input from the coauthors and coin-
vestigators.
Study design
This was a prospective multicenter randomized (FSBP-
TSG ratio, 1:1) single-blinded therapeutic trial conducted
at 26 medical centers in the United States. The study was
fully approved by the institutional review boards of the
participating centers. All subjects gave informed consent.
Inclusion criteria
Male or nonpregnant, nonlactating female patients
older than 18 years were eligible for study inclusion if they
were scheduled to undergo elective PTFE grafting includ-
ing at least one end-to-side anastomosis of a PTFE graft to
the common femoral artery and could undergo hepariniza-
tion during the period of arterial occlusion.
Experimental procedure
Surgery and randomization. All subjects were given
or continued to receive preoperative aspirin therapy. At the
beginning of the operation, FSBP and TSG were both
prepared for use by the operating room staff. Patients
received heparin (70 IU/kg) before arterial clamping. For
operations with more than one anastomosis, the study
anastomosis was the last one completed. Because this was a
single-blinded study (study personnel could not be blinded
to the nature of the experimental vs control treatment),
randomization was delayed until all possible study proce-
dures were completed. All study anastomoses were per-
formed end-to-side with standardized needles and suture
material (C-1 needle, 5-0 polypropylene suture [Prolene;
Ethicon, Somerville, NJ). After sewing was completed, the
arterial clamps were released and additional sutures were
placed, as needed, until the study surgeon judged the
suture line secure. The arterial clamps were then reapplied,
and the randomization envelope was opened. Blood for
coagulation testing (activated clotting time, activated par-
tial thromboplastin time) was drawn at randomization. As
directed by randomization, experimental (FSBP) or control
(TSG) topical therapy was applied. Because the two treat-
ments being compared function through different mecha-
nisms, the experimental procedure varied according to the
treatment to which each subject was randomized. For TSG
to function, autogenous fibrinogen must be present. The
procedure provided for this with application of TSG simul-
taneously with release of the vascular clamps. FSBP func-
tions by forming nonautogenous fibrin clot, which requires
time to form. The procedure provided for this by leaving
the vascular clamps in place after application of the FSBP.
Thrombin-soaked gelatin sponge. Gelatin sponge
was cut into appropriate sized rectangles and soaked in
thrombin solution before randomization. After randomiza-
tion, TSG was applied to the anastomosis, followed by
manual pressure within 20 seconds with gauze 4  4
surgical sponges, and the arterial clamps were released. The
anastomosis was observed until hemostasis occurred or
until 10 minutes after randomization. The intervals be-
tween release of sponge pressure to observe for hemostasis
were left to individual surgeon judgment.
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Fibrin sealant. The fibrin sealant used for this study,
Beriplast P (Aventis Behring) consists of two solutions. The
first includes human fibrinogen, coagulation factor XIII,
and aprotinin; the second includes human thrombin and
calcium chloride. Each solution was reconstituted and
drawn into a syringe. The two syringes were mounted into
a device (Pantaject; Aventis Behring) that allowed simulta-
neous mixing and application. The study procedure after
randomization consisted of application of FSBP to the
suture lines within 20 seconds of randomization while the
vascular clamps remained in place. The vascular clamps
were left in place for 3 minutes, the time required for a firm
fibrin clot to form from the applied FSBP, and then re-
leased. The protocol did not specify use of pressure from
surgical sponges in addition to FSBP. The anastomosis was
observed until hemostasis occurred or until 10 minutes
after randomization.
Primary end point
To allow fair comparison of the two approaches to
hemostasis, the primary end point for the study was defined
in terms of time from randomization, not time from treat-
ment application or time from clamp release, to hemostasis.
For this study, hemostasis was defined as a state in which
there was no detectable bleeding from the anastomosis site,
as judged by the operating surgeon. The primary end point
for the study was hemostasis at 4 minutes (30 seconds)
after randomization. This interval was chosen because the
study procedures required approximately 4 minutes after
randomization; thus hemostasis at 4 minutes was essentially
equivalent to no bleeding from the anastomotic site.
Secondary end points
The secondary end points for this study included actual
time from randomization to hemostasis, time from ran-
domization to beginning of wound closure, measured vol-
ume of blood loss at the anastomosis as determined with
weighed sponges, incidence of repeat bleeding, duration of
intensive care unit (ICU) stay, length of hospital stay,
postoperative mortality, and comprehensive adverse event
analysis.
Safety procedures
The experimental procedure could be terminated at
any time after randomization if, in the judgment of the
operating surgeon, blood loss was unacceptably excessive.
The experimental procedure was terminated if hemostasis
was not achieved within 10 minutes after randomization,
and surgeon preference procedures were followed to
achieve hemostasis.
Pilot study
Because no participating surgeons were familiar with
use of the FSBP product and applicator device, and not all
surgeons were equally familiar with use of TSG, a pilot
study was carried out to encompass the learning curve and
ensure equivalent familiarity with the study procedures.
Randomization in the pilot study was 2:1, FSBP to TSG.
Each participating surgeon was required to perform at least
one procedure under monitored observation with the study
techniques in the pilot study to participate in the primary
study.
Statistical analysis
The primary study end point, that is, hemostasis within
4 minutes of randomization, and all secondary efficacy end
points were analyzed with the intention-to-treat method.
The analysis was limited to subjects included in the main
study. A sample size of 200 randomized subjects was cho-
sen at the investigators’ planning meeting, based on an
estimated treatment effect of 25%. The two-sided 95% CI
for the common odds ratio stratified by surgeon for treat-
ment success, that is, hemostasis achieved within 4 minutes,
and the corresponding P value were obtained by exact
inference using the statistical package StatXact 4.0.
RESULTS
Pilot study subjects. One hundred eleven subjects
were enrolled in the pilot study. FSBP treatment was given
to 68 subjects, and TSG treatment to 30 subjects. Not
treated were 7 subjects who underwent surgery that was
delayed, canceled, or not performed according to protocol;
3 subjects with saphenous vein grafts; and 3 subjects who
were withdrawn for miscellaneous reasons.
Primary study subjects. Two hundred thirty-five
subjects were enrolled in the primary study. Not random-
ized were 34 subjects, for the following reasons: use of
saphenous vein (n  7); no bleeding (n  2); surgery
cancelled, delayed, or not performed according to protocol
(n 17); other exclusion criteria (n 8). Data for 1 of 201
randomized subjects was excluded from intention-to- treat
analysis because surgery was aborted before completion of
the vascular graft. This left 200 randomized subjects with
data analyzed with the intention-to-treat method. Of these,
199 actually received study treatment (FSBP, n  100;
TSG, n  99). There was no treatment cross-over. Demo-
graphic characteristics of the randomized subjects are com-
pared in Table I. There were no significant differences
between groups. The most frequent procedure performed
was femoropopliteal bypass grafting (65 subjects, 33%),
followed by aortobifemoral bypass grafting (55 subjects,
25%). Overall, 58% of subjects underwent outflow proce-
Table I. Subject characteristics
FSBP
(n  101)
TSG
(n  99)
P*n % n %
Male gender 64 63 61 62 .884
Age (mean, y) 63 65 .208
White race 88 87 81 82 .333
Height (mean, cm) 169 170 .696
Weight (mean, kg) 78 74 .188
FSBP, Fibrin sealant Beriplast P; TSG, thrombin-soaked gelatin sponge.
*Student t test for continuous variables and 2 test for categorical variables.
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dures (the study anastomosis was the proximal anastomo-
sis) and 43% of subjects underwent inflow procedures (the
study anastomosis was the distal anastomosis). There were
no significant differences between randomized groups with
respect to procedure performed or outflow versus inflow
procedure (data not shown).
Coagulation status. Coagulation status of the ran-
domized subjects is shown in Table II. There were no
differences between the two groups with respect to aspirin
use, heparin dose, or activated clotting time or activated
partial thromboplastin time at randomization.
Application of hemostatic agents. Time required to
initiate FSBP treatment was slightly, but not significantly,
shorter than for TSG (19.3 18.9 seconds vs 25.1 32.5
seconds; P  .013, Student t test). Time required to
complete application of the hemostatic agent was signifi-
cantly longer for TSG than for FSBP (33.8 20.9 seconds
vs 147.1  129.1 seconds; P  .0001, Student t test).
Because the procedure for FSBP required 3 minutes of
arterial clamping for annealing time after application of the
hemostatic agent, total treatment time (application plus
clamping) was significantly longer than total treatment
time for TSG (212  22 seconds vs 147.1  129.1 sec-
onds; P  .0001, Student t test).
Primary end point. Hemostasis at 4 minutes was
achieved in 64 subjects (63%) in the FSBP group and 40
subjects (40%) in the TSG group. The odds ratio for
treatment success for FSBP compared with TSG was 2.74
(95% CI, 1.42-5.41; P  .0018, two-sided exact test for
stratified 2  2 tables). There was no evidence that treat-
ment success with FSBP was surgeon dependent (P 
.7948, Zelen test for homogeneity of odds ratios).
Secondary end points. Within 3 minutes after ran-
domization, hemostasis was achieved in 12 subjects treated
with TSG. Hemostasis was not achieved before 3 minutes
in any subjects treated with FSBP, as dictated by the study
procedures. Overall time to hemostasis was significantly
shorter in the FSBP group (median, 4.0 minutes; 95% CI,
3.80-4.18 minutes) compared with the TSG group (medi-
an, 5.6 minutes; 95% CI, 4.50-7.00; P  .008, stratified
generalized Wilcoxon-Gehan test). Cumulative percentage
of subjects in each group in which hemostasis was achieved
is shown as a function of time in Fig 1.
Blood loss was measured in 192 of 200 subjects. Me-
dian blood loss was 4.0 g (SD, 29.7 g; n 95) in the FSBP
group and 15.6 g (SD, 28.4 g; n  97) in the TSG group.
The difference was significant (P  .0001, stratified Wil-
coxon-Mann-Whitney test).
The study anastomosis was the last anastomosis com-
pleted in 171 subjects (86%). For these subjects, median
time from randomization to beginning of wound closure
was 15.0 minutes (95% CI, 10.47-18.67 minutes; n  83)
in the FSBP group and 22.8 minutes (95% CI, 18.67-
30.67; n  88) in the TSG group. The difference was
significant (P  .005, stratified generalized Wilcoxon-Ge-
han test). The percentage of subjects with beginning
wound closure is shown in Fig 2 as a function of time.
There was no difference in proportion of subjects included
in this analysis between the FSBP and TSG groups (83% vs
88%; P  NS).
There was no difference in duration of ICU stay be-
tween the two groups (FSBP: median, 2 days; 95% CI,
2.0-2.0, vs TSG: median, 2 days; 95% CI, 2.00-3.00; P 
.4489, stratified generalized Wilcoxon-Gehan test). Over-
all hospital stay was longer in the TSG group (FSBP:
median 6.5 days; 95% CI, 5.00-7.00, vs TSG: median, 7.0
days; 95% CI, 6.00-8.00), and the difference approached
significance (P  .0565, stratified generalized Wilcoxon-
Gehan test).
Safety analysis. No termination of study procedures
(ie, within 10 minutes of randomization) was required in
either treatment group. In the FSBP group (n  100) two
(2%) subjects died within 30 days of surgery, and in the
TSG group (n 99) four (4%) subjects died within 30 days
of surgery (P  .448, exact Pearson 2 test). None of the
deaths was related to hemorrhage. Postoperative hemor-
rhage occurred in four subjects in the FSBP group (4%) and
in four subjects (4%) in the TSG group (P  1.0, exact
Pearson 2 test). Other adverse events are listed in Table
III (online only). The only significant difference between
the FSBP and TSG groups was in incidence of insomnia, an
effect with no plausible relationship to the study
treatments.
A list of laboratory studies obtained preoperatively and
postoperatively is presented in Table IV (online only).
There were significant changes between preoperative and
postoperative values in a number of tests, but there was no
difference in the changes that occurred with respect to
whether subjects received FSBP or TSG (P  NS for all
comparisons; data not shown). None of the laboratory test
changes that occurred were related to the study medica-
tion, in the opinion of the investigators. No adverse se-
quelae related to the longer period of arterial clamping (3
minutes) were recognized in the FSBP group.
DISCUSSION
Topical hemostatic aids of several kinds are in wide-
spread use in many types of surgery. Some agents, such as
oxidized cellulose or gelatin sponge, provide a matrix, or
scaffold, on which formation of autogenous clot is facili-
tated. Others, such as topical thrombin, accelerate autoge-
Table II. Coagulation status in randomized subjects
FSBP
(n  101)
TSG
(n  99)
P*n % n %
Aspirin use 85 84 85 87 .834
Heparin use 100 99 98 99 1.000
Heparin dose (mean IU) 6759 7355 .126
ACT (mean, s) 233 241 .391
APTT (mean, s) 142 143 .856
FSBP, Fibrin sealant Beriplast P; TSG, thrombin-soaked gelatin sponge;
ACT, activated clotting time at randomization; APTT, activated partial
thromboplastin time at randomization.
*Student’s t test for continuous variables and 2 test for categorical variables.
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nous clot formation. Fibrin sealants contain both fibrino-
gen and thrombin, which, when mixed, actively form
thrombus, without need for any component of the autog-
enous coagulation system. The present study was intended
to test the safety and efficacy of FSBP. The comparator,
TSG, was chosen by consensus of the investigators as the
most effective available nonfibrin sealant topical hemostatic
aid.
The experimental procedure was designed to produce a
clinically relevant end point. The primary end point for this
trial, hemostasis at 4 minutes, was chosen by consensus of
the investigators. Since the experimental procedure (apply-
ing and annealing the FSBP) consumed approximately 4
minutes, the investigators believed a truly effective hemo-
static aid would result in no bleeding at the end of the
experimental procedure and would enable immediate pro-
ceeding to wound closure. This end point was achieved in
63% of subjects treated with FSBP, a statistically signifi-
cantly greater percentage than was achieved with the com-
parator, TSG (40%).
Fig 1. Cumulative distribution of time from randomization to hemostasis for subjects treated with fibrin sealant (solid
line; n  100) versus subjects treated with thrombin-soaked gelatin sponge (broken line; n  99).
Fig 2. Cumulative distribution of time from randomization to start of wound closure for subjects treated with fibrin
sealant (solid line; n  83) versus subjects treated with thrombin-soaked gelatin sponge (broken line; n  88). Note:
Only subjects whose study anastomosis was the last anastomosis performed were included in this analysis (n  171).
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Achieving hemostasis after arterial vascular surgery pro-
cedures involves two elements, blood loss and time re-
quired. Analysis of secondary end points in this trial showed
that each was affected by the choice of topical hemostatic
aid. Blood loss was significantly less in FSBP-treated sub-
jects (mean, 4 g for FSBP vs 16 g for TSG; P  .0001).
Although the difference was significant, the actual volume
of blood lost was small and not clinically relevant, because
bleeding was controlled with pressure while waiting for
hemostasis, in keeping with good surgical practice and
patient safety. That time to beginning of wound closure
was also significantly sooner in the FSBP group confirms
that the more effective hemostasis achieved was clinically
relevant and enabled shortening of operative time.
There was a nearly significant trend toward shorter
hospital stay in the FSBP group (P .0565), although the
reason for this difference is not clear, as there were no more
complications in either group. It is not clear that shorter
operating time in and of itself produces shorter hospital
stay.
It is important to note that this study involved a specific
model system, testing the effectiveness of FSBP on bleed-
ing from needle and suture holes in PTFE grafts only. Most
vascular surgeons are familiar with the occasional pro-
longed need for pressure or other methods to achieve
hemostasis in this situation. Although use of FSBP for
topical hemostasis in other situations and locations in pe-
ripheral vascular surgery may be logical, this study neither
confirms nor refutes its effectiveness in such situations. It is
possible that the outcome of this trial was influenced by lack
of a consistent approach to application of sponge pressure
or time between episodes of release of sponge pressure to
inspect for hemostasis in the TSG group, because this
interval was not specified by the protocol. Given the large
number of surgeons involved, a systematic difference seems
unlikely. The increased clamp time required to allow a firm
clot to form from FSBP may limit applicability of this
specific method to other vascular surgery operations, such
as those on the carotid artery.
Jackson et al7 studied the effectiveness of another fibrin
sealant versus TSG in achieving hemostasis after PTFE
patches were used to close carotid endarterectomy arteriot-
omies. There were no differences in their primary end
point, hemostasis within 15 minutes, or in time to hemo-
stasis or blood loss. Although the study was a randomized
trial, all aspects of the surgical procedure were not con-
trolled (ie, suture and needle use), and the fibrin sealant did
not contain fibrin stabilizing factor XIII or aprotinin. The
investigators noted poor adherence of the fibrin sealant to
the PTFE material. That FSBP contains fibrin stabilizing
factor XIII and the antithrombolytic aprotinin may in part
explain why the current trial showed effectiveness.
Milne et al8 studied fibrin sealant compared with no
treatment in a similar study of PTFE patches in carotid
endarterectomy, and found significantly improved time to
hemostasis with use of fibrin sealant. Rousou et al9 found
fibrin sealant superior to a number of comparators, such as
collagen, oxidized cellulose, gelatin sponge, and topical
bovine thrombin, in an evaluation of time to hemostasis in
repeat cardiac surgery.
Since use of commercial products to achieve hemostasis
involves additional cost, compared with use of direct pres-
sure only, cost-effectiveness is an issue. Although costs were
not assessed in the present study, the significantly decreased
time to beginning of wound closure and decreased length
of hospital stay both suggest that the cost of FSBP is offset
by cost gains in other areas. Since both of these differences
were small, whether either would have any meaningful
effect on cost remains open to question. This hypothesis
should be tested in further prospective studies.
FSBP is not the only hemostatic product that has been
evaluated for control of suture and needle hole bleeding
from PTFE grafts. Glickman et al10 demonstrated results
similar to those of the current study, using a polymeric
sealant compared with TSG.
In conclusion, in this prospective randomized clinical
trial FSBP was more effective than TSG in achieving hemo-
stasis of needle and suture hole bleeding from PTFE fem-
oral artery grafts. Measured blood loss and time to begin-
ning of wound closure were improved in the FSBP group.
Based on our findings, we conclude that FSBP is indicated
to help achieve hemostasis in PTFE femoral artery grafting.
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